Short answer
Cartesian Therapeutics, Inc. (RNAC) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 results for quarter ended June 30, 2026.
Cartesian Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026
- Press release furnished as Exhibit 99.1, containing financial results and management commentary
Item EX-99.1 · Exhibit EX-99.1
- Phase 3 AURORA MG data expected 1Q27, with BLA filing planned for mid-2027; primary value inflection for Descartes-08
- Cash, equivalents and restricted cash $149.3M, supporting planned operations into 2028 alongside four expected clinical readouts
- K2HV facility provides up to $150M non-dilutive financing, though $50M optional tranche remains subject to lender discretion
- WestGene partnership adds an in vivo CAR-T program, with Phase 1 initiation expected 2H26 and clinical data expected 1H27
- R&D expense rose to $20.4M from $14.9M, while quarterly net income $15.8M primarily reflected a $49.2M contingent-value-rights liability gain
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Cartesian Therapeutics, Inc. 8-K filings
Get the next RNAC 8-K as it lands
Follow RNAC for push alerts, or ask the research agent what this filing means.